Cita APA

Danto, S. I., Shojaee, N., Singh, R. S. P., Li, C., Gilbert, S. A., Manukyan, Z., & Kilty, I. (2019). Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects. BMC.

Citación estilo Chicago

Danto, Spencer I., Negin Shojaee, Ravi Shankar P. Singh, Cheryl Li, Steven A. Gilbert, Zorayr Manukyan, and Iain Kilty. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Selective Interleukin-1 Receptor-associated Kinase 4 (IRAK4) Inhibitor, in Single and Multiple Ascending Dose Randomized Phase 1 Studies in Healthy Subjects. BMC, 2019.

Cita MLA

Danto, Spencer I., et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Selective Interleukin-1 Receptor-associated Kinase 4 (IRAK4) Inhibitor, in Single and Multiple Ascending Dose Randomized Phase 1 Studies in Healthy Subjects. BMC, 2019.